<DOC>
	<DOC>NCT00265655</DOC>
	<brief_summary>To determine the objective response rate (ORR) of oral satraplatin in patients with Metastatic Breast Cancer.</brief_summary>
	<brief_title>Satraplatin for Patients With Metastatic Breast Cancer (MBC)</brief_title>
	<detailed_description>This is a Phase II open label, nonrandomized study for patients with metastatic breast cancer. WHAT IS SATRAPLATIN: Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Satraplatin</mesh_term>
	<criteria>1. Has cytologically or pathologically confirmed breast cancer that is metastatic 2. Must have had prior Herceptin√í therapy if patient has HER2+ (overexpressing) breast cancer. HER2 is considered overexpressed if it is 3+ by IHC or if the gene is amplified by Flourescence in situ hybridization (FISH) 3. Has had no more than 1 prior chemotherapy regimen for MBC 4. Has had no prior platinumbased therapy 5. Has an ECOG Performance Status (PS) 02</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>